


PRODUCT INFORMATION



Artemisinin

Item No. 11816

CAS Registry No.: 63968-64-9
Formal Name: (3R,5aS,6R,8aS,9R,12S,12aR)-octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10(3H)-one
Synonym: NSC 369397
MF: C₁₅H₂₂O₅
FW: 282.3
Purity: ≥98%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Artemisinin is supplied as a crystalline solid. A stock solution may be made by dissolving the artemisinin in the solvent of choice. Artemisinin is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of artemisinin in these solvents is approximately 16, 10, and 20 mg/ml, respectively.

Artemisinin is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, artemisinin should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Artemisinin has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Artemisinin is an antimalarial agent with anticancer activity.^{1,2} It is an iron(II) oxide-reactive endoperoxide that generates reactive oxygen species (ROS) upon cleavage of its endoperoxide bridge.³ It reduces the growth of various *P. falciparum* strains *in vitro* (IC₅₀s = 3.98-20.36 nM) and reduces parasitemia in mice infected with *P. falciparum* with a curative dose (CD₅₀) value of 140 mg/kg.^{1,4} It also reduces *P. berghei* infection in mice (ED₅₀ = 5.6 mg/kg per day).⁵ Artemisinin (100-400 μM) induces cell cycle arrest in the G₀/G₁ phase and apoptosis and inhibits growth of SK-N-AS, BE(2)-C, SK-N-DZ, and SHEP1 neuroblastoma cells in a time- and concentration-dependent manner.² It also suppresses BE(2)-C cell colony formation in a soft agar assay and reduces tumor growth in a BE(2)-C mouse xenograft model. Formulations containing artemisinin have been used in combination therapies for the treatment of malaria.

References

1. Akoachere, M., Buchholz, K., Fischer, E., *et al.* *Antimicrob. Agents Ch.* **49(11)**, 4592-4597 (2005).
2. Zhu, S., Liu, W., Ke, X., *et al.* *Oncol. Rep.* **32(3)**, 1094-1100 (2014).
3. Ooko, E., Saeed, M.E.M., Kadioglu, O., *et al.* *Phytomedicine* **22(11)**, 1045-1054 (2015).
4. Robert, A., Benoit-Vical, F., Claparols, C., *et al.* *Proc. Natl. Acad. Sci. U.S.A.* **102(38)**, 13676-13680 (2005).
5. Chawira, A.N., Warhurst, D.C., Robinson, B.L., *et al.* *Trans. R. Soc. Trop. Med. Hyg.* **81(4)**, 554-558 (1987).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/14/2018

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM